Two new RSV vaccine candidates, made by Pfizer and GlaxoSmithKline, could become the world’s first approved shots against the common respiratory syncytial virus (RSV). The FDA, which typically follows the committee’s recommendations, is expected to decide on approval in May, ahead of RSV’s typical winter surge.